Advertisement Sinus Dynamics Introduces Nasally-inhaled Aerosolized Form Of Vancomycin - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Sinus Dynamics Introduces Nasally-inhaled Aerosolized Form Of Vancomycin

Vancomycin, for the treatment of MRSA

Sinus Dynamics has discovered treatment for Methicillin Resistant Staphylococcus Aureus (MRSA) with a nasally-inhaled aerosolized form of Vancomycin, which can help patients and hospitals limit exposure to asymptomatic MRSA carriers.

Vancomycin is used to treat bacterial infections by stopping or killing the bacteria responsible. The company claims that when treatment using other antibiotics has failed, Vancomycin is the strongest option available in the market.

The company is said to be prepared to work with physicians and hospital administrators to implement this infection control therapy, in an effort to help reduce MRSA infections across the country.

Sinus Dynamics works with otolaryngologists, allergy & immunology specialists, infectious disease specialists, and pulmonary specialists throughout the US; providing custom compounded medications, exclusively formulated to treat upper respiratory infections and inflammation through topical treatment.